Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v3.22.2.2
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 56,391 $ 376,976
Investments in marketable securities, current 235,294 0
Prepaid expenses and other current assets 6,807 4,760
Total current assets 298,492 381,736
Restricted cash, non-current 1,716 1,716
Investments in marketable securities, non-current 13,403 0
Property and equipment, net 13,270 6,507
Operating lease right-of-use assets 7,120 11,574
Other assets 844 454
Total assets 334,845 401,987
Current liabilities:    
Accounts payable 3,972 2,453
Accrued compensation 3,346 2,689
Accrued research costs 353 633
Accrued expenses and other current liabilities 1,297 886
Operating lease liabilities, current 4,556 5,482
Total current liabilities 13,524 12,143
Operating lease liabilities, non-current 2,451 5,794
Other long- term liabilities 2,417 0
Total liabilities 18,392 17,937
Commitments and contingencies (Note 7)
Stockholders’ equity:    
Preferred stock, $0.00001 par value, 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; and no shares issued and outstanding as of September 30, 2022 and December 31, 2021 0 0
Common stock, $0.00001 par value, 300,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 58,149,317 and 58,010,823 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 1 1
Additional paid-in-capital 535,852 525,400
Accumulated other comprehensive loss (1,596) 0
Accumulated deficit (217,804) (141,351)
Total stockholders’ equity 316,453 384,050
Total liabilities and stockholders’ equity $ 334,845 $ 401,987